10:10 - 11:40 amSaturday, September 17
Lower Lobby
Designing for good patient decisions: bringing together data, psychology, and human-centered design to help breast cancer survivors choose a method of post-treatment surveillance.
Lower Lobby
Designing for good patient decisions: bringing together data, psychology, and human-centered design to help breast cancer survivors choose a method of post-treatment surveillance.
Ph.D., Assistant Investigator, Group Health Research Institute
Mammograms are the standard for post-treatment surveillance of breast cancer patients, but the use of MRI is rising due to doctors and women developing anecdotal experience through peers and through its... Read more

Description

Mammograms are the standard for post-treatment surveillance of breast cancer patients, but the use of MRI is rising due to doctors and women developing anecdotal experience through peers and through its usage in other processes like diagnosis. Few data are available to guide decisions about which method is more effective for individual patients, and many patients are unaware of the important implications of their choice on their time, money, stress, and comfort. Group Health Research Institute (GHRI) and Artefact are working to help fill this important gap by bringing together the first large-scale data analysis of MRI and mammography to support clinical decisions and developing an interactive decision-support system with individually calculated patient results. In this panel discussion, together with GHRI, we will share lessons learned, design principles and behavioral economics strategies that we have deployed to create a platform that can empower more effective and confident decision-making by breast cancer patients.

An epidemiologist and 10-year veteran of the Fred Hutchinson Cancer Research Center, Dr. Wernli joined Group Health Research Institute (GHRI) in 2009 and began a three-year career development award in comparative effectiveness research in 2010. The award’s rich coursework, mentorship, and training opportunities support her goal of answering key questions related to cancer screening and diagnostics.

She is now leading a Patient-Centered Outcomes Research Institute (PCORI) contract to compare breast MRI (magnetic resonance imaging) to mammography for women already treated for breast cancer. There is little evidence to support the use of breast MRI for surveillance when physicians are looking for second breast cancers or recurrences of the first cancer. She is working with the Breast Cancer Surveillance Consortium (BCSC) to evaluate these two technologies. Also through the BCSC, Dr. Wernli leads a study using data on more than 800,000 women aged 40 to 79 to determine if mammographic breast density is linked to the risk of developing ovarian cancer. Additionally she is a co-investigator of GHRI’s Colorectal Cancer Screening Registry, which is part of the National Cancer Institute’s Population-based Research Optimizing Screening through Personalized Regimens (PROSPR) program. 

Dr. Wernli serves as a reviewer for several journals, including the American Journal of Epidemiology andCancer Epidemiology, Biomarkers & Prevention. A longtime member of the American Society for Preventive Oncology (ASPO), she was a recipient of the Prevent Cancer Foundation/ASPO Cancer Prevention Fellowship in 2009 and served as co-chair for the annual meeting workshop with their Young Investigators.

Contact Us

We're not around right now. But you can send us an email and we'll get back to you, asap.

Not readable? Change text. captcha txt

Start typing and press Enter to search